Core Viewpoint - The announcement details the share reduction plan executed by shareholders of Baotai Biopharmaceutical Co., Ltd., highlighting the completion of the reduction and the current shareholding status of the involved parties [1][4]. Group 1: Shareholder Information - Before the reduction plan, Xinyu Qiheng Management Consulting Partnership (Limited Partnership) and its acting in concert party, Huitianze Investment Co., Ltd., collectively held 20,704,000 shares, accounting for 5.00% of the total share capital of Baotai Biopharmaceutical [2]. Group 2: Reduction Plan Implementation - The reduction plan disclosed on April 24, 2025, allowed Xinyu Qiheng to reduce up to 8,281,600 shares, representing no more than 2% of the total share capital, with a maximum of 4,140,800 shares to be sold via centralized bidding and another 4,140,800 shares through block trading [3]. - The reduction period was set to commence 15 trading days after the announcement and would last for three months, with adjustments to the number of shares to be reduced in case of any capital changes [3]. Group 3: Reduction Results - As of August 19, 2025, Xinyu Qiheng reported a reduction of 3,216,877 shares through centralized bidding, which is 0.78% of the total shares, with no shares sold via block trading [4]. - Post-reduction, Xinyu Qiheng and Huitianze collectively hold 17,487,123 shares, which is 4.22% of the total share capital [4]. - The reduction plan was completed as scheduled, and the actual reduction matched the previously disclosed plan [5][6].
百奥泰生物制药股份有限公司股东减持股份结果公告